Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
进行中（未招募）
1
20.0%
招募中
4
80.0%
暂无批准数据
- Novartis' Phase 3 HARBOR study of del-desiran failed to show statistically significant improvement over placebo on video hand opening time in myotonic dystrophy type 1. - The antibody oligonucleotide conjugate targets DMPK messenger RNA, and Novartis reported clinical activity on secondary endpoints and exploratory analyses including muscle strength. - Novartis shares fell about 9-10% while Dyne Therapeutics and Sarepta Therapeutics dropped sharply on read-through risk to their related DMPK programs. - Novartis is evaluating the full HARBOR dataset and will engage health authorities on a development path; no approved treatment exists for the disease itself.
- RAPS has named three regulatory affairs professionals as its 2026 Fellows, honoring sustained leadership contributions to the profession and their organizations. - Shekhar Natarajan of Dyne Therapeutics is recognized for nearly three decades of experience and advocacy in rare disease drug development and regulatory policy. - Ola Oyinloye of Novo Nordisk and Mike Ryan, formerly of the FDA, are honored for advancing regulatory strategy across devices, combination products, and digital health. - The new Fellows will be formally recognized at RAPS Convergence 2026, held 15-17 September in Charlotte, North Carolina.
- Dyne Therapeutics is transitioning to a commercial-stage company with z-rostudirsen for Duchenne muscular dystrophy under FDA priority review and a PDUFA date of January 21. - The FORCE platform uses an antibody fragment to deliver oligonucleotides to muscle cells and across the blood-brain barrier, enabling higher dosing than previously possible. - In DMD, z-rostudirsen targets Exon 51 skipping and has shown roughly 10-fold higher dystrophin levels than the current standard, with functional improvements across all major measures. - A registrational expansion cohort readout in myotonic dystrophy type 1 is anticipated in the first quarter, with interim data to be presented at upcoming conferences.
- Eight biotech companies raised a record $3.5 billion in a single night following the American Society of Hematology conference, marking the busiest day ever in biotech fundraising. - Terns Pharmaceutical led the surge with a $650 million offering after presenting Phase I leukemia trial data showing 64% response rates, with potential peak sales projected at $2.5 billion. - Fulcrum Therapeutics raised $175 million following positive Phase Ib results for its sickle cell disease treatment in expectant mothers, demonstrating meaningful increases in fetal hemoglobin levels. - The fundraising wave reflects strong biotech sector performance with the NYSE Arca Biotechnology Index up 27% year-to-date, driven by positive trial results and increased M&A activity.
- The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the recommended newborn screening panel, enabling earlier detection of the rare genetic disorder. - This decision significantly expands the eligible patient pool for Sarepta Therapeutics' preventative DMD therapies and improves payer reimbursement prospects. - Sarepta faces mounting competition from Dyne Therapeutics, whose DYNE-251 candidate showed 5.46% dystrophin expression compared to Sarepta's Exondys 51 at 0.3-1% levels. - Despite competitive pressures, analysts project Sarepta will return to profitability in 2026 with estimated revenues of $1.59 billion and EPS of $2.23.
- Dyne Therapeutics plans to seek accelerated U.S. approval for z-rostudirsen, an exon skipping therapy that increased muscle-protecting protein levels by more than 5% in Duchenne muscular dystrophy patients with exon 51 mutations. - Kymera Therapeutics shares rose over 50% following positive data for KT-621, an oral protein-degrading drug showing "biologic-like or better efficacy" in atopic dermatitis markers. - Wave Life Sciences stock nearly doubled after WVE-007 demonstrated a 9% reduction in visceral fat and 4% decline in total body fat in early obesity trials. - Despite regulatory uncertainties in the Duchenne field, analysts noted Dyne's functional data represents the "best ever generated" for this drug class in placebo-controlled trials.
- Dyne Therapeutics' z-rostudirsen achieved a statistically significant 5.46% dystrophin expression in the Phase 1/2 DELIVER trial, representing a 7-fold increase from baseline in patients with Duchenne muscular dystrophy amenable to exon 51 skipping. - The therapy demonstrated functional improvements across multiple clinical endpoints at 6 months, with sustained benefits observed through 24 months in long-term extension studies. - The company plans to submit for U.S. Accelerated Approval in Q2 2026, targeting a potential Q1 2027 launch for approximately 1,600 eligible patients with significant unmet medical needs.
- Dyne Therapeutics shares dropped nearly 17% on Tuesday after the company announced a $300 million underwritten public offering, with underwriters holding an option for an additional $45 million. - The biotech plans to use proceeds to advance development programs, including its promising Duchenne muscular dystrophy treatment zeleciment rostudirsen following successful phase 1/2 trial results. - The significant dilution concerns investors as the offering represents over 10% of the company's $2.6 billion market capitalization. - Despite the market reaction, the company maintains a strong cash position of $791.9 million as of Q3 2025, projected to fund operations into late 2027.
- Dyne Therapeutics announced one-year data from the Phase 1/2 ACHIEVE trial showing sustained functional improvements with zeleciment basivarsen at 6.8 mg/kg in six adults with myotonic dystrophy type 1. - The investigational therapy demonstrated meaningful improvements across multiple measures including muscle strength, myotonia, upper and lower limb function, and patient-reported outcomes. - New data revealed improvements in manual dexterity via the 9-Hole Peg Test and comprehensive muscle strength gains across all tested muscle groups in both upper and lower extremities. - Both patients and physicians reported meaningful improvements in overall disease burden, with the therapy showing a favorable safety profile across 56 enrolled patients.
- Dyne Therapeutics' DYNE-302 demonstrated functional improvement in a severe FSHD mouse model, with a single intravenous dose restoring treadmill running ability at peak muscle weakness. - The siRNA-based therapy targets DUX4 mRNA and showed correction of muscle damage and inflammation markers in skeletal muscle tissue analysis. - Results suggest that preexisting and severe skeletal muscle disease in FSHD may be reversible through DUX4 mRNA targeting, offering hope for the estimated 16,000-38,000 affected individuals in the United States. - The findings will be presented at the 32nd Annual FSHD Society's International Research Congress in Amsterdam on June 13, 2025.
